Expression of FOXM1 and Aurora-A predicts prognosis and sorafenib efficacy in patients with hepatocellular carcinoma

Autor: Chang-Shen Lin, Kung-Kai Kuo, Wen-Tsan Chang, King-Teh Lee, Yu-Chu Wang, Jian-Wei Huang, Lin-An Chen, Shen-Nien Wang, Shih-Chang Chuang, Wen-Lung Su
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Oncology
Male
Cancer Research
Datasets as Topic
Aurora-A
hepatocellular carcinoma (HCC)
Medicine
Aurora Kinase A
Aged
80 and over
05 social sciences
Cell Cycle
Liver Neoplasms
General Medicine
Cell cycle
Middle Aged
Sorafenib
Prognosis
Up-Regulation
Gene Expression Regulation
Neoplastic
Liver
Hepatocellular carcinoma
Cohort
embryonic structures
Biomarker (medicine)
Female
biological phenomena
cell phenomena
and immunity
050104 developmental & child psychology
medicine.drug
Research Article
Adult
medicine.medical_specialty
Carcinoma
Hepatocellular
Adolescent
Disease-Free Survival
Young Adult
Internal medicine
Cell Line
Tumor
Genetics
Biomarkers
Tumor
Humans
0501 psychology and cognitive sciences
Gene
0505 law
Aged
business.industry
Forkhead Box Protein M1
FOXM1
medicine.disease
digestive system diseases
Drug Resistance
Neoplasm
Concomitant
050501 criminology
Neoplasm Recurrence
Local
business
Follow-Up Studies
Zdroj: Cancer Biomarkers
ISSN: 1875-8592
1574-0153
Popis: Background Effective prognostic biomarkers and powerful target-therapeutic drugs are needed for improving the treatment of Hepatocellular carcinoma (HCC). Objective This study aimed to evaluate the expression of FOXM1 and Aurora-A and their prognostic value in HCC. Methods We determined the differentially expressed genes signature in HCC using the Gene Set Enrichment Analysis (GSEA), and then evaluated the expression of FOXM1 and Aurora-A in TCGA and KMUH cohort. Associations between co-expression of FOXM1 and Aurora-A and clinical variables were calculated. Overall survival (OS) and recurrence-free survival (RFS) were estimated with different FOXM1 and Aurora-A expression status. Results FOXM1-related gene sets were mostly associated with cell cycle regulation in HCC tissues. We found a positive correlation between the expression of FOXM1 and Aurora-A. Overexpression of FOXM1 and Aurora-A was associated with larger tumor size, advanced stage, higher grade, and double-positive for HBV and HCV. The coordinated overexpression of FOXM1 and Aurora-A was the most significant independent prognostic factor for OS and RFS. Furthermore, the concomitant high expression of FOXM1 and Aurora-A predicted the worst OS of sorafenib-treated patients with HCC. Conclusions The co-expression of FOXM1 and Aurora-A could be a reliable biomarker to predict the sorafenib response and prognosis of HCC patients.
Databáze: OpenAIRE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje